Geron Corporation (FRA:GON)

Market Cap	1.02B -41.9%
Revenue (ttm)	156.31M +522.1%
Net Income	-68.18M
EPS	-0.10
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	6,605
Open	1.609
Previous Close	1.628
Day's Range	1.609 - 1.609
52-Week Range	0.915 - 2.478
Beta	n/a
RSI	80.79
Earnings Date	Feb 25, 2026

About Geron

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Employees: 229
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GON

Financial Performance

In 2024, Geron's revenue was $76.99 million, an increase of 32386.92% compared to the previous year's $237,000. Losses were -$174.57 million, -5.19% less than in 2023.

Financial numbers in USD